Palobiofarma S.L is a Spanish biotechnology company founded in 2006 by a group of scientists with experience in drug discovery in several pharmaceutical companies.
The mission of the Palobiofarma is to discover new drugs based on the modulation of adenosine receptors.
The Vision of Palobiofarma is to discover the first marketed drug based on a selective adenosine receptor modulator.
Palobiofarma focused internal resources on areas where lies the experience of the management team:
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as the pharmacology and toxicology tests, are carried out through partnerships with various companies (CROs), Research Centres and Universities.
Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome
Palobiofarma
Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
Palobiofarma
Palobiofarma S.L. anuncia resultados positivos del ensayo de fase 2 de PBF-680 oral en pacientes con EPOC moderada a grave
Palobiofarma
Palobiofarma anuncia la finalización del ensayo clínico de fase II con su terapia en investigación PBF-680 en pacientes con enfermedad pulmonar obstructiva crónica (EPOC)
Palobiofarma
La FDA y la Comisión Europea conceden la Designación de Medicamento Huérfano a PBF-999 para el tratamiento del Síndrome de Prader-Willi
Palobiofarma
Palobiofarma cierra una ronda de 7M€ con la participación de Inveready, Sodena y el equipo promotor
Palobiofarma
El potencial de un fármaco de Palobiofarma para tratar una enfermedad pediátrica rara es validado por la agencia americana del medicamento
Palobiofarma
Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome
Palobiofarma
Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome
Palobiofarma
Medibiofarma cierra nueva ronda de financiación por valor de 1,2 millones de euros
Palobiofarma
